Institutional BioSafety Committee (IBC)

The mission of the Duke University IBC is to:

  1. Ensure that all recombinant DNA (rDNA) research conducted at the institution or sponsored by the institution is conducted in compliance with the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines).

    NIH Definition of recombinant DNA (from this point forward termed rDNA) includes:
    1. Molecules that a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids
    2. Nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or
    3. Molecules that result from the replication of those described in (i) or (ii) above.
  2. Respond to requests from other institutional entities (e.g., Employee Occupational Health and Wellness, Division of Laboratory Animal Resources) or individuals for other types of biosafety review.

IBC Policies-Procedures
Scheduled Meetings for 2022
Scheduled Meetings for 2021

IBC Members

The Duke IBC membership includes individuals representing a variety of scientific disciplines.  This diverse group was selected to provide the appropriate oversight of the various types of rDNA research conducted at Duke.  The Committee is currently co-chaired by Dr. Wayne Thomann, Assistant Clinical Professor, Family Medicine and Community Health, Director, Occupational & Environmental Safety, and Dr. Richard Frothingham, Associate Professor, Dept. of Medicine - Infectious Diseases.

Please feel free to contact either co-chair with questions:

Dr. Thomann

Ph: 919-684-6320

Dr. Frothingham

Ph: 919-684-5455